Doxorubicin Hydrochloride

Doxorubicin hydrochloride is an antitumor antibiotic of the anthracycline series. Has a wide spectrum of antitumor effects.

general information

Producing countries: Russia, India.

Pharmgroup: antitumor antibiotics.

Manufacturers: Bryntsalov (Russia), Deko (Russia), Lance-Pharm (Russia), Mediafarm (Russia), Rusan Pharma (India), etc.

International titles: doxorubicin.

Synonyms: adriamycin, adriblastin, blastocin, doxolem, doxorubicin-Lance, doxorubicin-Teva, doxorubicin-Ferein, doxorubicin-Ebeve, kelix, rastocin.

Dosage forms: powder for injection, lyophilisate for solution.

Compound: doxorubicin (active ingredient).

Properties and application

1. It is used for leukemia, lymphoma, breast, lung, bladder, ovarian, and sarcoma cancers.

2. It has antitumor, immunosuppressive and cardiotoxic effects.

3. It is administered intravenously, intracavity or intravesical.

4. Before use, the lyophilisate is dissolved in water for injection.

Contraindications

1. Hypersensitivity to doxorubicin, severe dysfunction of the liver, kidneys, heart, hematopoiesis, peptic ulcer of the stomach and duodenum, pregnancy, breastfeeding.

2. Prescribe with caution to patients over 70 years of age.

Side effects

1. Hematopoietic inhibition, cardiotoxicity, nausea, vomiting, diarrhea, stomatitis, alopecia, allergic reactions.

2. Locally: pain and burning (with intravesical administration).

Use during pregnancy and breastfeeding

Contraindicated during pregnancy and breastfeeding.

Overdose

Symptoms: severe inhibition of hematopoiesis, damage to the mucous membranes.
Treatment: symptomatic, transfusion of blood and its components, use of colony-stimulating factors.

Interaction

Increases the toxicity of other antitumor and radiation therapy. Weakens the effect of vaccines. Incompatible with heparin, dexamethasone and other drugs.

special instructions

During the treatment period, it is necessary to monitor blood counts, liver function, and heart function. It is advisable to carry out dental procedures before starting therapy. Application requires compliance with aseptic rules.

You can start a second course after hematopoiesis has been restored. Prescribe with caution in case of reduced bone marrow reserve. Do not mix with other antitumor drugs.